Araujo F G, Hunter C A, Remington J S
Research Institute, Palo Alto Medical Foundation, CA 94301, USA.
Antimicrob Agents Chemother. 1997 Jan;41(1):188-90. doi: 10.1128/AAC.41.1.188.
The capacity of interleukin 12 (IL-12) to potentiate drugs in the treatment of murine toxoplasmosis was examined. IL-12 (100 ng/injection), atovaquone (10 mg/kg of body weight/day), or clindamycin (5 mg/kg/day) administered alone caused delayed time to death or minimal survival rates. In contrast, significant survival rates resulted when the same dose of IL-12 was used in combination the same doses of atovaquone (P=0.01) or clindamycin (P=0.001). Infected mice treated with IL-12 plus drug produced significantly higher levels of gamma interferon than controls. Although IL-12 was effective only when administered before infection, these results suggest that this cytokine may be a useful adjunct in the therapy of human toxoplasmosis in situations when cysts reactivate and tachyzoites start multiplying in immunocompromised patients.
研究了白细胞介素12（IL-12）增强药物治疗小鼠弓形虫病的能力。单独给予IL-12（每次注射100 ng）、阿托伐醌（10 mg/kg体重/天）或克林霉素（5 mg/kg/天）会导致死亡时间延迟或存活率极低。相比之下，当相同剂量的IL-12与相同剂量的阿托伐醌（P=0.01）或克林霉素（P=0.001）联合使用时，存活率显著提高。用IL-12加药物治疗的感染小鼠产生的γ干扰素水平明显高于对照组。虽然IL-12仅在感染前给药时有效，但这些结果表明，在免疫功能低下患者中囊肿重新激活且速殖子开始增殖的情况下，这种细胞因子可能是治疗人类弓形虫病的有用辅助药物。
